AI For Data Analysis In Pharmacy-Based Trials, Alexion's vs. AstraZeneca's Recruitment & Engagement Strategies, and More
Clinical Leader
A resource and forum to investigate and resolve the common struggles related to running effective clinical trials.
Welcome to the Clinical Trial Insights newsletter, featuring strategic insights and expert opinions on designing and running clinical trials. Each edition covers the latest trending articles on ClinicalLeader.com.
In this week's issue, we'll review the potential of leveraging AI for data analysis in pharmacy-based trials, the underlying causes of patient attrition, the differences in Alexion's and AstraZeneca's recruitment and engagement strategies for rare diseases vs. chronic conditions, myths about electronic data capture, and other popular insights.
If you like what you're seeing in our condensed LinkedIn editions, subscribe to our daily newsletter for full access to exclusive articles, webinars, e-books, and more! Subscribe Now →
Clinical Leader Solutions Expo: eCOA / ePRO Supplier Showcase
Join our virtual Solutions Expo on April 3rd, where industry leaders will showcase the eCOA and ePRO solutions of partners who are ready to help you with your clinical trial data capture needs!
TOP 5 READS OF THE PAST WEEK
Clinical trials in the pharmacy setting present unique benefits to pharmaceutical sponsors, pharmacies, and patients. Sandy Kim shares how leveraging artificial intelligence for data analysis in pharmacy-based trials holds immense potential for revolutionizing drug development and healthcare delivery.
A substantial 15% to 40%?of patients exit clinical trials before completion. Patient attrition not only incurs significant costs but also poses a substantial obstacle to the success and validity of a trial. In this article, Scout delves into an exploration of patient attrition in clinical trials, examining its underlying causes and the profound impact it can have on the success of medical research.
领英推荐
Rare disease and chronic conditions, when it comes to studying their interventions in clinical trials, have similarities as well as differences — from protocol feasibility to patient recruitment and retention tactics. Consider the rare disease portfolio at Alexion Pharmaceuticals, Inc. and chronic conditions in the 阿斯利康 portfolio.
For those involved with managing the flow of clinical trial data, the ability to pull an increasing amount of data directly from the source has led many to wonder if their existing electronic data capture system can handle all of this change. To help researchers develop an accurate view of the EDC landscape, this piece by Crucial Data Solutions, Inc. will seek to identify and bust some of the key myths surrounding the future of EDC in clinical trials.
For rare diseases like pulmonary fibrosis, additional research is needed to help aid medical professionals with the struggle to care for and treat each patient. In an effort to increase and diversify research, the Pulmonary Fibrosis Foundation envisioned a new approach to aggregating usable medical data — asking patients directly. Learn more about their new community registry.
MORE TO EXPLORE
Clinical Leader is an online community serving professionals in the clinical research space. We share insights and best practices — from industry experts — to help sponsors and CROs tackle the biggest challenges they face in designing and running clinical trials.
To get the most out of our offerings, join the Clinical Leader community.